Korea's largest '2022 IVRA International Medical Conference' to be held

On the 25th, Protocols of COVID-19, cancer treatment, and pain management were presented and the latest knowledge was shared at COEX.

The '2022 IVRA International Medical Conference' (IVRA, International Virus Research Alliance), a gathering of medical staff and scholars from over 30 countries around the world, will be held in Room 401 of COEX Conference Room in Samseong-dong, Seoul on June 25.

At this conference, ambassadors to Korea and high-ranking foreign government officials from over 30 countries around the world will participate to present protocols for treating Covid-19 virus, cancer, and pain management, and share successful treatment results from around the world. The conference provides an opportunity to share various methods and latest knowledge.

The presenters at the event were IVRA Chairman and Professor Lee Kang-Hyeon of Wonju Yonsei University College of Medicine, IVRA Research Committee Chairman and Professor Jang Hong-Seok of the Catholic University of Korea, IVRA Co-Chairman and Chungcheongnam-do Health and Healthcare Subcommittee Chairman Dr. Seungmo Yoo, IVRA Vice Chairman and Yonsei Family Love Clinic Director Kim Seon-Man, and Cancer Hospital Nanabiti Hospital, India. Specialist Dr. Nagraj, oncologist Dr. Damodara of Ponticherry Hospital in India, Professor Yoo Hwa-seung, director of Daejeon University's Seoul Oriental Hospital, Director Yang Jae-ho, director of Chihyu Oriental Medicine Hospital (Jongno), Director Jang Hyuk-jun of Chihyu Oriental Medicine Hospital (Dogok), and President Lee Hyeong-min of the Korean Academy of Emergency Medicine Medical Association. , Malaysian cancer specialist Dr. Laci, Chinese cancer specialist Professor Wu Zibing, Malaysian cancer specialist Dr. Ho, Malaysian cancer specialist Dr. Izzati, and AdipoLABs CEO Han Sung-ho.

In particular, foreign guests attending the event on this day included Raed Arafat (currently Secretary of State of the Romanian Ministry of the Interior and Director of the National Emergency Situations Office), Manaudo Malić (currently Minister of Health and Welfare of Cameroon), Jagutupal (Minister of Health and Welfare of Mauritius), and Nevel Matidje (Minister of Health and Welfare of South Africa), and Managing Director of Trade Strategy and Operations), Mohammed Jinnah (Chairman of the UNWHD), and Zaim Cruz (Chairman of Philippine PLC Group)

Among the contents to be announced at this IVRA is 'the effect of hyperthermia treatment related to viral infection, cancer, and pain'. In particular, Seosan Medical Center in South Chungcheong Province and Seoul St. Mary's Hospital have collaborated to conduct clinical treatment on about 25 COVID-19 positive patients since May of last year. They will introduce meaningful research results from treatment-related medical staff.

Based on the theory that hyperthermia immunotherapy has a positive effect on overcoming viruses when using a high-frequency hyperthermia device, an attempt was made to combine it with hyperthermia immunotherapy. Through this treatment using the medical high-frequency thermotherapy device REMISSION 1℃, they discovered the principle that hythermia treatment is effective, and it will serve as a treatment guide to move toward the end of COVID-19. Particularly, significant research results have been confirmed in the treatment of asymptomatic or mild patients, prevention of conversion to severe disease, and prevention of various diseases through hyperthermia immune treatment.

High-frequency hyperthermia involves applying high-frequency waves to the human body, generating frictional heat due to rotation, collision, and twisting of ionic charges within cells due to the intersection of + and - charges. The main principle of high-frequency hyperthermia therapy is to increase deep heat in the human body through this, and when deep heat rises, blood circulation and immunity increase, especially treating viruses, inflammation, and cancer that are vulnerable to heat. AdipoLABs' high-frequency hyperthermia therapy device, REMISSION 1℃, received official medical device approval from the Ministry of Food and Drug Safety in 2015 and is being used to treat numerous patients at home and abroad. The device has attracted tremendous attention of medical officials at major domestic and international exhibitions.

Han Sung-ho, CEO of AdipoLABs, said, “Despite the difficulties facing the world due to the COVID-19 pandemic, REMISSION 1°C has improved the health of many COVID-19 patients. The clinical results showed very meaningful results, such as not a single patient progressing from severe disease to death. It has been proven to be effective in cancer treatment and pain relief. By donating REMISSION 1℃ to IVRA overseas member countries, we will prove the effectiveness for patients infected with the COVID-19 virus and cancer patients. The device will be very effective in treating cancer and relieving pain. We will strive to provide overseas medical support,”

링크 : https://www.medipana.com/article/view.php?news_idx=299038&sch_cate=B